Orelabrutinib Combined With Pola-R-CHP as First-Line Treatment for Patients With Intermediate- to High-Risk DLBCL

To evaluate orelabrutinib in combination with polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) as first-line treatment for patients with intermediate- to high-risk diffuse large B-cell lymphoma (DLBCL).

Trial Details

NCT ID
NCT07778212
Phase
NA
Sponsor
The First Affiliated Hospital of Xiamen University
Status
RECRUITING
Cancer Type
Diffuse Large B-Cell (DLBCL) Lymphoma
Interventions
  • Orelabrutinib Combined with Pola-R-CHP Regimen
Locations (sample)
  • Xiamen, Fujian, China|24.47979,118.08187
  • Xiamen, Fujian, China|24.47979,118.08187

Key Eligibility Criteria

  • Aged ≥ 18 years;
  • Pathologically confirmed diffuse large B-cell lymphoma (DLBCL) by tumor tissue, with at least one measurable lesion, including DLBCL, not otherwise…
  • No prior receipt of other anti-tumor treatments;
  • ECOG performance status 0-2;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Diffuse Large B-Cell (DLBCL) Lymphoma Trials on Trialify →